Christine M. Lovly, MD, PhD
Although immunotherapy has become an important modality for treating non–small cell lung cancer (NSCLC), the development of new strategies for targeting oncogenic drivers of disease in subgroups of patients is moving forward at a brisk pace.
The 2019 American Society of Clinical Oncology Annual Meeting (ASCO 2019) featured early findings for several promising novel therapies aimed at challenging less common targets in slices of the lung cancer mutation pie.
These emerging therapies and the aberrations they target include AMG 510, KRAS
G12C mutations; BLU-667, RET
fusions; capmatinib and tepotinib, MET
exon 14 skipping mutations (MET
ex14); and TAK-788, EGFR
exon 20 insertion mutations.
... to read the full story